Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siponimod effects on chronic intrathecal inflammation in active progressive multiple sclerosis
2023-000142-42Phase 4Active
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of siponimod in secondary-progressive multiple sclerosis (SPMS) and multiple sclerosis (MS), sponsored by Azienda Ospedaliera Universitaria Integrata Verona. Primary endpoint: Change in cerebrospinal fluid CXCL13 level. Started Jan 2023; status: active.
02
Drugs
siponimod
03
Conditions
secondary-progressive multiple sclerosis (SPMS)multiple sclerosis (MS)
Beyond the preview
Go deeper on 2023-000142-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-000142-42.